Tumorigenesis of PCai1 cells in vivo was stronger than that of LNCaP, therefore, to demonstrate the effect of NCL1 in prostate cancer, we used PCai1 in the in vivo study. The gene discussed is CAPN3; the disease is Familial prostate cancer.